Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jun;84(6):834-872.
doi: 10.1016/j.jinf.2022.02.026. Epub 2022 Feb 27.

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2

Jackelinne Y Hayashi  1 , Adriana Simizo  1 , Jackson G Miyamoto  1 , Lucas V S Costa  2 , Olívia F Souza  2 , Tassia Chiarelli  1 , Natália B S Bacarov  3 , Rafaela Hidalgo  3 , Letícia D Garcia  3 , Michel M Soane  3 , Carla T Braconi  2 , Juliana T Maricato  2 , Luiz M Janini  2 , Reinaldo Salomão  4 , Ana F Popi  2 , Isaias Glezer  1 , Tatiana Bonetti  5 , Alexandre K Tashima  6
Affiliations
Comment

Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2

Jackelinne Y Hayashi et al. J Infect. 2022 Jun.
No abstract available

Keywords: Antibodies; BNT162b2; Booster; COVID-19; ChAdOx1; CoronaVac; Interferon-gamma; Neutralizing; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest NBSB, RH, LDG and MMS are employees of EUROIMMUN Brasil. All other authors have nothing to declare.

Figures

Fig 1
Fig. 1
(A) Experimental design of this study. Healthcare professional volunteers vaccinated with two homologous doses of CoronaVac and with a heterologous third dose of BNT162b2 (CV/CV/BNT) or with two homologous doses of ChAdOx1 and with a heterologous third dose of BNT162b2 (Ch/Ch/BNT). Blood samples were collected at t0–t4 for CV/CV/BNT and at t0’–t4’ for Ch/Ch/BNT. Humoral and cellular responses were evaluated by the levels of anti-S1 IgG, neutralizing antibodies, and IFN-γ. (B) Dynamics of humoral responses in vaccinated volunteers after two homologous doses of CoronaVac followed by a third dose with BNT162b2 (CV/CV/BNT) or after two homologous doses of ChAdOx1 followed by a third dose with BNT162b2 (Ch/Ch/BNT).
Fig 2
Fig. 2
(A) Levels of neutralizing antibodies and (B) IFN-γ after homologous vaccination with CoronaVac followed by a third dose with BNT162b2 (CV/CV/BNT) or after homologous vaccination with ChAdOx1 followed by a third dose with BNT162b2 (Ch/Ch/BNT).
See this image and copyright information in PMC

Comment on

References

    1. Mak Willem A., Koeleman Johannes G.M., van der Vliet Marijke, Keuren Frans, Ong David S.Y. SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: a prospective cohort study. J Infect. 2022;84(2):171–178. doi: 10.1016/j.jinf.2021.12.003. - DOI - PMC - PubMed
    1. Salim Karim, Abdool S., Abdool Karim Quarraisha. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet. 2021;398(10317):2126–2128. doi: 10.1016/S0140-6736(21)02758-6/ATTACHMENT/B8C47DC8-B485-4240-95DD-FF7ADBB31E18/MMC1.PDF. - DOI - PMC - PubMed
    1. Smriti Mallapaty. China's COVID vaccines have been crucial — now immunity is waning. Nature. 2021;598(7881):398–399. doi: 10.1038/D41586-021-02796-W. - DOI - PubMed
    1. Mok Chris Ka, Pun Cheng, Samuel M.S., Chunke Chen, Karen Yiu, Tat-On Chan, Cheung Lai Kiu, et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. MedRxiv. 2021 doi: 10.1101/2021.11.02.21265843. 2021.11.02.21265843. - DOI
    1. Munro Alasdair P.S., Leila Janani, Victoria Cornelius, Aley Parvinder K., Gavin Babbage, David Baxter, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–2276. doi: 10.1016/S0140-6736(21)02717-3. - DOI - PMC - PubMed